KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Total Debt (2016 - 2025)

Gilead Sciences' Total Debt history spans 17 years, with the latest figure at $24.9 billion for Q4 2025.

  • For Q4 2025, Total Debt fell 6.65% year-over-year to $24.9 billion; the TTM value through Dec 2025 reached $24.9 billion, down 6.65%, while the annual FY2025 figure was $24.9 billion, 6.65% down from the prior year.
  • Total Debt reached $24.9 billion in Q4 2025 per GILD's latest filing, roughly flat from $24.9 billion in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $30.2 billion in Q2 2021 to a low of $23.2 billion in Q3 2024.
  • Average Total Debt over 5 years is $25.8 billion, with a median of $25.2 billion recorded in 2022.
  • The largest YoY upside for Total Debt was 25.2% in 2021 against a maximum downside of 14.99% in 2021.
  • A 5-year view of Total Debt shows it stood at $26.7 billion in 2021, then fell by 5.49% to $25.2 billion in 2022, then dropped by 0.96% to $25.0 billion in 2023, then increased by 6.9% to $26.7 billion in 2024, then fell by 6.65% to $24.9 billion in 2025.
  • Per Business Quant, the three most recent readings for GILD's Total Debt are $24.9 billion (Q4 2025), $24.9 billion (Q3 2025), and $24.9 billion (Q2 2025).